SHSE:600285 (China)
Â
Class A
Â¥
25.45
(+5.38%)
Apr 30
Business Description
Henan Lingrui Pharmaceutical Co Ltd
NAICS : 325411
SIC : 2834
ISIN : CNE000001501
Share Class Description:
SHSE:600285: Class ACompare
Compare
Traded in other countries / regions
600285.China IPO Date
2000-10-18Description
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 42.11 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.05 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 6.14 | |||||
| Beneish M-Score | -2.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.5 | |||||
| 3-Year EBITDA Growth Rate | 19.1 | |||||
| 3-Year EPS without NRI Growth Rate | 21.3 | |||||
| 3-Year FCF Growth Rate | 28 | |||||
| 3-Year Book Growth Rate | 6.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.77 | |||||
| 9-Day RSI | 69.36 | |||||
| 14-Day RSI | 68.81 | |||||
| 6-1 Month Momentum % | 35.59 | |||||
| 12-1 Month Momentum % | 28.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.49 | |||||
| Quick Ratio | 1.26 | |||||
| Cash Ratio | 0.77 | |||||
| Days Inventory | 184.51 | |||||
| Days Sales Outstanding | 28 | |||||
| Days Payable | 28.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.36 | |||||
| Dividend Payout Ratio | 0.55 | |||||
| 3-Year Dividend Growth Rate | 26 | |||||
| Forward Dividend Yield % | 2.36 | |||||
| 5-Year Yield-on-Cost % | 11.1 | |||||
| Shareholder Yield % | 2.57 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.16 | |||||
| Operating Margin % | 19.06 | |||||
| Net Margin % | 17.9 | |||||
| FCF Margin % | 22.03 | |||||
| ROE % | 22.45 | |||||
| ROA % | 13.22 | |||||
| ROIC % | 25.34 | |||||
| ROC (Joel Greenblatt) % | 106.07 | |||||
| ROCE % | 24.9 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.46 | |||||
| PE Ratio without NRI | 23.2 | |||||
| Shiller PE Ratio | 43.41 | |||||
| Price-to-Owner-Earnings | 25.27 | |||||
| PEG Ratio | 1.56 | |||||
| PS Ratio | 4.2 | |||||
| PB Ratio | 4.92 | |||||
| Price-to-Tangible-Book | 5.33 | |||||
| Price-to-Free-Cash-Flow | 19.11 | |||||
| Price-to-Operating-Cash-Flow | 18.59 | |||||
| EV-to-EBIT | 18.45 | |||||
| EV-to-EBITDA | 18.45 | |||||
| EV-to-Revenue | 3.77 | |||||
| EV-to-FCF | 17.12 | |||||
| Price-to-Projected-FCF | 1.33 | |||||
| Price-to-DCF (Earnings Based) | 0.74 | |||||
| Price-to-DCF (FCF Based) | 0.61 | |||||
| Price-to-Median-PS-Value | 1.42 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.39 | |||||
| Price-to-Graham-Number | 2.35 | |||||
| Price-to-Net-Current-Asset-Value | 16.01 | |||||
| Earnings Yield (Greenblatt) % | 5.42 | |||||
| FCF Yield % | 5.24 | |||||
| Forward Rate of Return (Yacktman) % | 20.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Henan Lingrui Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,431.871 | ||
| EPS (TTM) (Â¥) | 1.085 | ||
| Beta | 1.12 | ||
| Volatility % | 31.86 | ||
| 14-Day RSI | 68.81 | ||
| 14-Day ATR (Â¥) | 0.987042 | ||
| 20-Day SMA (Â¥) | 22.7515 | ||
| 12-1 Month Momentum % | 28.37 | ||
| 52-Week Range (Â¥) | 14.3 - 25.77 | ||
| Shares Outstanding (Mil) | 567.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Henan Lingrui Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Henan Lingrui Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Henan Lingrui Pharmaceutical Co Ltd Frequently Asked Questions
What is Henan Lingrui Pharmaceutical Co Ltd(SHSE:600285)'s stock price today?
The current price of SHSE:600285 is ¥25.45. The 52 week high of SHSE:600285 is ¥25.77 and 52 week low is ¥14.30.
When is next earnings date of Henan Lingrui Pharmaceutical Co Ltd(SHSE:600285)?
The next earnings date of Henan Lingrui Pharmaceutical Co Ltd(SHSE:600285) is .
Does Henan Lingrui Pharmaceutical Co Ltd(SHSE:600285) pay dividends? If so, how much?
The Dividend Yield %  of Henan Lingrui Pharmaceutical Co Ltd(SHSE:600285) is 2.36% (As of Today), Highest Dividend Payout Ratio of Henan Lingrui Pharmaceutical Co Ltd(SHSE:600285) was 0.77. The lowest was 0.26. And the median was 0.55. The  Forward Dividend Yield % of Henan Lingrui Pharmaceutical Co Ltd(SHSE:600285) is 2.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers